ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.
- The joint venture will fulfill the unmet global manufacturing and production needs of this coveted radioisotope.
- The collaboration also encompasses the development and implementation of the manufacturing process to be used at the APF.
- ITM will also be responsible for global marketing, sales, and distribution, which will be supported by its well-established global sales network.
- “Working with ITM, CNL has already made significant progress towards our goal of bringing a next-generation medical radioisotope to the world market.